The tale of TILs in breast cancer : a report from The International Immuno-Oncology Biomarker Working Group

Bairi El; H.R. Haynes; E. Blackley; S. Fineberg; J. Shear; S. Turner; Juliana Ribeiro de Freitas; D. Sur; L.C. Amendola; M. Gharib; A. Kallala; I. Arun; F. Azmoudeh-Ardalan; L. Fujimoto; L.F. Sua; S.-W. Liu; H.-C. Lien; P. Kirtani; M. Balancin; Attar El; P. Guleria; W. Yang; E. Shash; I.-C. Chen; V. Bautista; Prado Do; B.L. Rapoport; C. Castaneda; E. Spengler; G. Acosta-Haab; I. Frahm; J. Sanchez; M. Castillo; N. Bouchmaa; Zin Md; R. Shui; T. Onyuma; W. Yang; Z. Husain; K. Willard-Gallo; A. Coosemans; E.A. Perez; E. Provenzano; P.G. Ericsson; E. Richardet; R. Mehrotra; S. Sarancone; A. Ehinger; D.L. Rimm; J.M.S. Bartlett; G. Viale; The International Immuno-Oncology Biomarker Working Group; Ewan Millar; al et al

doi:10.1038/s41523-021-00346-1

The tale of TILs in breast cancer : a report from The International Immuno-Oncology Biomarker Working Group

Bairi El
, H.R. Haynes
, E. Blackley
, S. Fineberg
, J. Shear
, S. Turner
, Juliana Ribeiro de Freitas
, D. Sur
, L.C. Amendola
, M. Gharib
, A. Kallala
, I. Arun
, F. Azmoudeh-Ardalan
, L. Fujimoto
, L.F. Sua
, S.-W. Liu
, H.-C. Lien
, P. Kirtani
, M. Balancin
, Attar El

P. Guleria, W. Yang, E. Shash, I.-C. Chen, V. Bautista, Prado Do, B.L. Rapoport, C. Castaneda, E. Spengler, G. Acosta-Haab, I. Frahm, J. Sanchez, M. Castillo, N. Bouchmaa, Zin Md, R. Shui, T. Onyuma, W. Yang, Z. Husain, K. Willard-Gallo, A. Coosemans, E.A. Perez, E. Provenzano, P.G. Ericsson, E. Richardet, R. Mehrotra, S. Sarancone, A. Ehinger, D.L. Rimm, J.M.S. Bartlett, G. Viale, The International Immuno-Oncology Biomarker Working Group, Ewan Millar, al et al

Western Sydney University

Research output: Contribution to journal › Article › peer-review

234 Citations (Scopus)

2 Downloads (Pure)

Abstract

The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings. A subgroup of women with breast cancer (BC) has immunogenic infiltration of lymphocytes with expression of programmed death-ligand 1 (PD-L1). These patients may potentially benefit from ICI targeting the programmed death 1 (PD-1)/PD-L1 signaling axis. The use of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarkers has been under intense examination. Emerging data suggest that TILs are associated with response to both cytotoxic treatments and immunotherapy, particularly for patients with triple-negative BC. In this review from The International Immuno-Oncology Biomarker Working Group, we discuss (a) the biological understanding of TILs, (b) their analytical and clinical validity and efforts toward the clinical utility in BC, and (c) the current status of PD-L1 and TIL testing across different continents, including experiences from low-to-middle-income countries, incorporating also the view of a patient advocate. This information will help set the stage for future approaches to optimize the understanding and clinical utilization of TIL analysis in patients with BC.

Original language	English
Article number	150
Number of pages	17
Journal	npj Breast Cancer
Volume	7
Issue number	1
DOIs	https://doi.org/10.1038/s41523-021-00346-1
Publication status	Published - 1 Dec 2021

Bibliographical note

Publisher Copyright:
© 2021, The Author(s).

Open Access - Access Right Statement

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1038/s41523-021-00346-1

Tale_open_access

Cite this

El, B., Haynes, H. R., Blackley, E., Fineberg, S., Shear, J., Turner, S., Ribeiro de Freitas, J., Sur, D., Amendola, L. C., Gharib, M., Kallala, A., Arun, I., Azmoudeh-Ardalan, F., Fujimoto, L., Sua, L. F., Liu, S.-W., Lien, H.-C., Kirtani, P., Balancin, M., ... et al, A. (2021). The tale of TILs in breast cancer : a report from The International Immuno-Oncology Biomarker Working Group. npj Breast Cancer, 7(1), Article 150. https://doi.org/10.1038/s41523-021-00346-1

@article{6f9c1b2c33954c4a8d442cf69bf5d015,

title = "The tale of TILs in breast cancer : a report from The International Immuno-Oncology Biomarker Working Group",

abstract = "The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings. A subgroup of women with breast cancer (BC) has immunogenic infiltration of lymphocytes with expression of programmed death-ligand 1 (PD-L1). These patients may potentially benefit from ICI targeting the programmed death 1 (PD-1)/PD-L1 signaling axis. The use of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarkers has been under intense examination. Emerging data suggest that TILs are associated with response to both cytotoxic treatments and immunotherapy, particularly for patients with triple-negative BC. In this review from The International Immuno-Oncology Biomarker Working Group, we discuss (a) the biological understanding of TILs, (b) their analytical and clinical validity and efforts toward the clinical utility in BC, and (c) the current status of PD-L1 and TIL testing across different continents, including experiences from low-to-middle-income countries, incorporating also the view of a patient advocate. This information will help set the stage for future approaches to optimize the understanding and clinical utilization of TIL analysis in patients with BC.",

author = "Bairi El and H.R. Haynes and E. Blackley and S. Fineberg and J. Shear and S. Turner and \{Ribeiro de Freitas\}, Juliana and D. Sur and L.C. Amendola and M. Gharib and A. Kallala and I. Arun and F. Azmoudeh-Ardalan and L. Fujimoto and L.F. Sua and S.-W. Liu and H.-C. Lien and P. Kirtani and M. Balancin and Attar El and P. Guleria and W. Yang and E. Shash and I.-C. Chen and V. Bautista and Prado Do and B.L. Rapoport and C. Castaneda and E. Spengler and G. Acosta-Haab and I. Frahm and J. Sanchez and M. Castillo and N. Bouchmaa and Zin Md and R. Shui and T. Onyuma and W. Yang and Z. Husain and K. Willard-Gallo and A. Coosemans and E.A. Perez and E. Provenzano and P.G. Ericsson and E. Richardet and R. Mehrotra and S. Sarancone and A. Ehinger and D.L. Rimm and J.M.S. Bartlett and G. Viale and \{The International Immuno-Oncology Biomarker Working Group\} and Ewan Millar and \{et al\}, al",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

month = dec,

day = "1",

doi = "10.1038/s41523-021-00346-1",

language = "English",

volume = "7",

journal = "npj Breast Cancer",

issn = "2374-4677",

publisher = "Nature Research",

number = "1",

}

El, B, Haynes, HR, Blackley, E, Fineberg, S, Shear, J, Turner, S, Ribeiro de Freitas, J, Sur, D, Amendola, LC, Gharib, M, Kallala, A, Arun, I, Azmoudeh-Ardalan, F, Fujimoto, L, Sua, LF, Liu, S-W, Lien, H-C, Kirtani, P, Balancin, M, El, A, Guleria, P, Yang, W, Shash, E, Chen, I-C, Bautista, V, Do, P, Rapoport, BL, Castaneda, C, Spengler, E, Acosta-Haab, G, Frahm, I, Sanchez, J, Castillo, M, Bouchmaa, N, Md, Z, Shui, R, Onyuma, T, Yang, W, Husain, Z, Willard-Gallo, K, Coosemans, A, Perez, EA, Provenzano, E, Ericsson, PG, Richardet, E, Mehrotra, R, Sarancone, S, Ehinger, A, Rimm, DL, Bartlett, JMS, Viale, G, The International Immuno-Oncology Biomarker Working Group, Millar, E & et al, A 2021, 'The tale of TILs in breast cancer : a report from The International Immuno-Oncology Biomarker Working Group', npj Breast Cancer, vol. 7, no. 1, 150. https://doi.org/10.1038/s41523-021-00346-1

TY - JOUR

T1 - The tale of TILs in breast cancer : a report from The International Immuno-Oncology Biomarker Working Group

AU - El, Bairi

AU - Haynes, H.R.

AU - Blackley, E.

AU - Fineberg, S.

AU - Shear, J.

AU - Turner, S.

AU - Ribeiro de Freitas, Juliana

AU - Sur, D.

AU - Amendola, L.C.

AU - Gharib, M.

AU - Kallala, A.

AU - Arun, I.

AU - Azmoudeh-Ardalan, F.

AU - Fujimoto, L.

AU - Sua, L.F.

AU - Liu, S.-W.

AU - Lien, H.-C.

AU - Kirtani, P.

AU - Balancin, M.

AU - El, Attar

AU - Guleria, P.

AU - Yang, W.

AU - Shash, E.

AU - Chen, I.-C.

AU - Bautista, V.

AU - Do, Prado

AU - Rapoport, B.L.

AU - Castaneda, C.

AU - Spengler, E.

AU - Acosta-Haab, G.

AU - Frahm, I.

AU - Sanchez, J.

AU - Castillo, M.

AU - Bouchmaa, N.

AU - Md, Zin

AU - Shui, R.

AU - Onyuma, T.

AU - Yang, W.

AU - Husain, Z.

AU - Willard-Gallo, K.

AU - Coosemans, A.

AU - Perez, E.A.

AU - Provenzano, E.

AU - Ericsson, P.G.

AU - Richardet, E.

AU - Mehrotra, R.

AU - Sarancone, S.

AU - Ehinger, A.

AU - Rimm, D.L.

AU - Bartlett, J.M.S.

AU - Viale, G.

AU - The International Immuno-Oncology Biomarker Working Group, null

AU - Millar, Ewan

AU - et al, al

PY - 2021/12/1

Y1 - 2021/12/1

N2 - The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings. A subgroup of women with breast cancer (BC) has immunogenic infiltration of lymphocytes with expression of programmed death-ligand 1 (PD-L1). These patients may potentially benefit from ICI targeting the programmed death 1 (PD-1)/PD-L1 signaling axis. The use of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarkers has been under intense examination. Emerging data suggest that TILs are associated with response to both cytotoxic treatments and immunotherapy, particularly for patients with triple-negative BC. In this review from The International Immuno-Oncology Biomarker Working Group, we discuss (a) the biological understanding of TILs, (b) their analytical and clinical validity and efforts toward the clinical utility in BC, and (c) the current status of PD-L1 and TIL testing across different continents, including experiences from low-to-middle-income countries, incorporating also the view of a patient advocate. This information will help set the stage for future approaches to optimize the understanding and clinical utilization of TIL analysis in patients with BC.

AB - The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings. A subgroup of women with breast cancer (BC) has immunogenic infiltration of lymphocytes with expression of programmed death-ligand 1 (PD-L1). These patients may potentially benefit from ICI targeting the programmed death 1 (PD-1)/PD-L1 signaling axis. The use of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarkers has been under intense examination. Emerging data suggest that TILs are associated with response to both cytotoxic treatments and immunotherapy, particularly for patients with triple-negative BC. In this review from The International Immuno-Oncology Biomarker Working Group, we discuss (a) the biological understanding of TILs, (b) their analytical and clinical validity and efforts toward the clinical utility in BC, and (c) the current status of PD-L1 and TIL testing across different continents, including experiences from low-to-middle-income countries, incorporating also the view of a patient advocate. This information will help set the stage for future approaches to optimize the understanding and clinical utilization of TIL analysis in patients with BC.

UR - http://hdl.handle.net/1959.7/uws:68508

U2 - 10.1038/s41523-021-00346-1

DO - 10.1038/s41523-021-00346-1

M3 - Article

SN - 2374-4677

VL - 7

JO - npj Breast Cancer

JF - npj Breast Cancer

IS - 1

M1 - 150

ER -

The tale of TILs in breast cancer : a report from The International Immuno-Oncology Biomarker Working Group

Abstract

Bibliographical note

Open Access - Access Right Statement

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this